Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, Avanish S. Bhakta, Patrick M. Boland, Michael J. Cavnar, Michelle L. Churchman, Hassan Hatoum, Lyen C. Huang, Joseph Kim, Richard Kim, Robert W. Lentz, Sarbajit Mukherjee, Mary T. O'Donnell, Benjamin Quartey, Matthew J. Reilley, Robert J. Rounbehler, Bodour Salhia, Bryan P. Schneider, Carlos H. Chan
{"title":"原癌基因HRAS转录水平与II期和III期结直肠癌的总生存率","authors":"Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, Avanish S. Bhakta, Patrick M. Boland, Michael J. Cavnar, Michelle L. Churchman, Hassan Hatoum, Lyen C. Huang, Joseph Kim, Richard Kim, Robert W. Lentz, Sarbajit Mukherjee, Mary T. O'Donnell, Benjamin Quartey, Matthew J. Reilley, Robert J. Rounbehler, Bodour Salhia, Bryan P. Schneider, Carlos H. Chan","doi":"10.1002/cam4.71114","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Mutational landscape is prognostic in colorectal cancer (CRC). <i>Rat sarcoma</i> (<i>RAS</i>) oncogenes, such as <i>KRAS</i> and <i>NRAS</i>, with driver mutations, portend poor survival outcomes, whereas pathologic mutations in <i>HRAS</i> are extremely rare, and their prognostic value remains uncertain.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study analyzed the Oncology Research Information Exchange Network (ORIEN) alliance tumor RNA-Seq data in Stages II and III CRC to investigate the association between <i>RAS</i> gene expression and survival outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>High transcript levels of <i>HRAS</i> were associated with superior overall survival (OS). The high <i>HRAS</i>-associated OS benefit was most pronounced in patients with right-sided primary expressing low <i>KRAS</i> transcript levels in the absence of pathologic <i>KRAS</i> mutations.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Contrary to the notion that <i>RAS</i> family genes are proto-oncogenic, this study demonstrates that high <i>HRAS</i> transcript levels are associated with superior OS in Stages II and III CRC. The potential of <i>HRAS</i> as a prognostic biomarker should be explored further.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71114","citationCount":"0","resultStr":"{\"title\":\"Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer\",\"authors\":\"Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, Avanish S. Bhakta, Patrick M. Boland, Michael J. Cavnar, Michelle L. Churchman, Hassan Hatoum, Lyen C. Huang, Joseph Kim, Richard Kim, Robert W. Lentz, Sarbajit Mukherjee, Mary T. O'Donnell, Benjamin Quartey, Matthew J. Reilley, Robert J. Rounbehler, Bodour Salhia, Bryan P. Schneider, Carlos H. Chan\",\"doi\":\"10.1002/cam4.71114\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Mutational landscape is prognostic in colorectal cancer (CRC). <i>Rat sarcoma</i> (<i>RAS</i>) oncogenes, such as <i>KRAS</i> and <i>NRAS</i>, with driver mutations, portend poor survival outcomes, whereas pathologic mutations in <i>HRAS</i> are extremely rare, and their prognostic value remains uncertain.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This retrospective study analyzed the Oncology Research Information Exchange Network (ORIEN) alliance tumor RNA-Seq data in Stages II and III CRC to investigate the association between <i>RAS</i> gene expression and survival outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>High transcript levels of <i>HRAS</i> were associated with superior overall survival (OS). The high <i>HRAS</i>-associated OS benefit was most pronounced in patients with right-sided primary expressing low <i>KRAS</i> transcript levels in the absence of pathologic <i>KRAS</i> mutations.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Contrary to the notion that <i>RAS</i> family genes are proto-oncogenic, this study demonstrates that high <i>HRAS</i> transcript levels are associated with superior OS in Stages II and III CRC. The potential of <i>HRAS</i> as a prognostic biomarker should be explored further.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 15\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71114\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71114\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71114","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer
Background
Mutational landscape is prognostic in colorectal cancer (CRC). Rat sarcoma (RAS) oncogenes, such as KRAS and NRAS, with driver mutations, portend poor survival outcomes, whereas pathologic mutations in HRAS are extremely rare, and their prognostic value remains uncertain.
Methods
This retrospective study analyzed the Oncology Research Information Exchange Network (ORIEN) alliance tumor RNA-Seq data in Stages II and III CRC to investigate the association between RAS gene expression and survival outcomes.
Results
High transcript levels of HRAS were associated with superior overall survival (OS). The high HRAS-associated OS benefit was most pronounced in patients with right-sided primary expressing low KRAS transcript levels in the absence of pathologic KRAS mutations.
Conclusions
Contrary to the notion that RAS family genes are proto-oncogenic, this study demonstrates that high HRAS transcript levels are associated with superior OS in Stages II and III CRC. The potential of HRAS as a prognostic biomarker should be explored further.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
